Skip to main content

Table 4 Clinicopathological characteristics according to EGFR mutation type

From: Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity

 

EGFR exon 19

EGFR exon 20

EGFR exon 21

EGFR negative

N

50

9

56 (L858R in 54)

98

Age

60.40 ± 8.83

64.22 ± 8.04

66.45 ± 8.80**

62.68 ± 11.35

Sex

M:F = 23:27

M:F = 4:5

M:F = 16:40**

55:43

PYR

8.09 ± 14.90

2.72 ± 6.55

4.68 ± 15.25**

14.03 ± 19.19

Pathologic stage

50

9

54*

95

  0

4

0

2

9

  IA

40

6

38

57

  IB

4

2

12

18

  IIA

0

0

1

5

  IIB

1

1

0

0

  IIIA

1

0

1

5

  IIIB

0

0

0

1

Nodal involvement

1

1

2

10

Histologic invasiveness

50

9

55†

98

  AIS

4

0

2

9

  MIA

7

0

4

5

  IA

39

9

49

84

Maximal diameter

21.294 ± 10.713

26.944 ± 12.692

22.950 ± 8.769

22.376 ± 12.052

Solid diameter

9.392 ± 11.754

16.489 ± 15.322

11.900 ± 10.303

12.559 ± 11.257

TDR

0.765 ± 0.283

0.592 ± 0.312

0.679 ± 0.296

0.692 ± 0.292

  1. *Data for pathologic stage were unavailable for 2 patients.
  2. †Data for histologic invasiveness were unavailable for 1 patient.
  3. **P value < 0.05 compared with EGFR-negative patients.